论文部分内容阅读
目的:探讨新型超声造影剂对肝纤维化-肝硬化定量诊断的研究。方法:肝纤维化、肝硬化患者各20例,均经肝穿刺病理证实,正常对照组10例,无任何肝脏病史,采用实时灰阶超声造影,团注法注入声诺维(SonoVue),测定肝静脉到达时间(HVAT)及肝动脉到达时间(HAAT),两者相减得到肝动静脉渡越时间(HA-VTT)。结果:HA-VTT在正常对照组、肝纤维化组、肝硬化组间两两比较均有统计学意义(P<0.05),肝硬化组HA-VTT较正常对照组明显缩短(P<0.01)。结论:利用新型超声造影剂测量HA-VTT有望成为定量诊断肝纤维化、肝硬化的新方法。
Objective: To investigate the new type of ultrasound contrast agent for the diagnosis of liver fibrosis - cirrhosis. Methods: Twenty patients with hepatic fibrosis and cirrhosis were confirmed by liver biopsy. Ten patients in the control group had no history of liver disease. Real-time gray-scale contrast echocardiography and SonoVue injection were performed. Hepatic Venous Access Time (HVAT) and Hepatic Artery Arrival Time (HAAT) were subtracted to obtain the hepatic arteriovenous transit time (HA-VTT). Results: HA-VTT was significantly different in normal control group, liver fibrosis group and cirrhosis group (P <0.05), and HA-VTT in liver cirrhosis group was significantly shorter than that in normal control group (P <0.01) . Conclusion: The use of a new ultrasound contrast agent for the measurement of HA-VTT is expected to be a new method for the quantitative diagnosis of liver fibrosis and cirrhosis.